Advertisement
CELZ vs IMRN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a Hold and IMRN is a Hold.
CELZ in downward trend: 10-day moving average moved below 50-day moving average on September 17, 2026
The 10-day moving average for CELZ crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CELZ as a result. In 87 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CELZ turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
CELZ moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELZ entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CELZ's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELZ advanced for three days, in 200 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.650) is normal, around the industry mean (2.835). P/E Ratio (-0.361) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CELZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IMRN in downward trend: price dove below 50-day moving average on September 23, 2026
IMRN moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 73 of 80 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMRN as a result. In 110 of 124 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IMRN turned negative on September 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 49 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
The 10-day moving average for IMRN crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 22 of 23 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for IMRN entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for IMRN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRN advanced for three days, in 141 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
IMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.710) is normal, around the industry mean (2.835). P/E Ratio (-1.980) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (1.622) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. IMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CELZ | IMRN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 86 | 64 | |
P/E GROWTH RATING 1..100 | 20 | 23 | |
SEASONALITY SCORE 1..100 | 85 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IMRN's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for CELZ (85) in the null industry. This means that IMRN’s stock grew somewhat faster than CELZ’s over the last 12 months.
IMRN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CELZ (100) in the null industry. This means that IMRN’s stock grew similarly to CELZ’s over the last 12 months.
IMRN's SMR Rating (97) in the Biotechnology industry is in the same range as CELZ (98) in the null industry. This means that IMRN’s stock grew similarly to CELZ’s over the last 12 months.
IMRN's Price Growth Rating (64) in the Biotechnology industry is in the same range as CELZ (86) in the null industry. This means that IMRN’s stock grew similarly to CELZ’s over the last 12 months.
CELZ's P/E Growth Rating (20) in the null industry is in the same range as IMRN (23) in the Biotechnology industry. This means that CELZ’s stock grew similarly to IMRN’s over the last 12 months.
| CELZ | IMRN | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 77% | 4 days ago 81% |
| Momentum ODDS (%) | 4 days ago 88% | 4 days ago 89% |
| MACD ODDS (%) | 4 days ago 88% | 4 days ago 89% |
| TrendWeek ODDS (%) | 4 days ago 87% | 4 days ago 88% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 88% |
| Advances ODDS (%) | 18 days ago 85% | 12 days ago 77% |
| Declines ODDS (%) | 6 days ago 85% | 8 days ago 86% |
| BollingerBands ODDS (%) | 6 days ago 90% | 4 days ago 88% |
| Aroon ODDS (%) | 4 days ago 85% | 4 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CELZ’s FA Score shows that 1 FA rating(s) are green while IMRN’s FA Score has 2 green FA rating(s).
- CELZ’s FA Score: 1 green, 4 red.
- IMRN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CELZ’s TA Score shows that 4 TA indicator(s) are bullish while IMRN’s TA Score has 4 bullish TA indicator(s).
- CELZ’s TA Score: 4 bullish, 6 bearish.
- IMRN’s TA Score: 4 bullish, 6 bearish.
Price Growth
CELZ (@Biotechnology) experienced а -11.63% price change this week, while IMRN (@Biotechnology) price change was -9.06% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.
Reported Earning Dates
CELZ is expected to report earnings on Dec 02, 2026.
IMRN is expected to report earnings on Dec 02, 2026.
Industries' Descriptions
@Biotechnology (-7.77% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CELZ and
Correlation & Price change
A.I.dvisor tells us that CELZ and WVE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELZ and WVE's prices will move in lockstep.
| Ticker / NAME | Correlation To CELZ | 1D Price Change % | ||
|---|---|---|---|---|
| CELZ | 100% | -9.39% | ||
| WVE - CELZ | 30% Poorly correlated | -1.88% | ||
| TRDA - CELZ | 29% Poorly correlated | -8.58% | ||
| GNPX - CELZ | 28% Poorly correlated | -7.86% | ||
| IOVA - CELZ | 26% Poorly correlated | -7.47% | ||
| ACET - CELZ | 26% Poorly correlated | -11.09% | ||
More | ||||